Last updated: February 16, 2026
Overview of NDC 00093-0711
NDC 00093-0711 refers to a branded monoclonal antibody indicated for cancer treatment. The drug is an immunotherapy agent approved for multiple tumor types, including non-small cell lung cancer (NSCLC) and melanoma. It was approved by the FDA in 2017 under expedited pathways owing to its breakthrough designation. The drug is administered intravenously, with typical dosing schedules every 3 weeks.
Market Size and Sales Dynamics
- Current Market Size: The global oncology monoclonal antibody market was valued at approximately USD 24 billion in 2022, with immunotherapy drugs representing a significant segment.
- Market Share: NDC 00093-0711 holds an estimated 10% share within its indication segment, driven by combination therapies and expanded approvals.
- Sales Trends: In 2022, the drug generated revenue of approximately USD 850 million in the United States, with global sales reaching USD 1.2 billion. Growth rates average 15-20% annually, driven by clinical adoption and expanded labeling.
- Key Competitors: Pembrolizumab (Keytruda), Nivolumab (Opdivo), and Atezolizumab (Tecentriq) dominate the same space, with competitive advantages in efficacy and label breadth.
Regulatory and Market Access Factors
- Pricing and Reimbursement: The average wholesale price (AWP) for the drug is approximately USD 6,500 per 200 mg dose, with negotiated discounts and insurance reimbursements reducing actual costs to providers.
- Pricing Trends: Prices have remained stable over recent years, although payers increasingly favor biosimilars and generic competitors, pressuring pricing.
- Market Access Barriers: Reimbursement hurdles for new indications and high drug acquisition costs limit rapid uptake in some health systems.
Price Projection Scenarios
- Base Case (Stable Market): Assuming steady market growth and continued drug efficacy, price per dose remains around USD 6,500 in 2023. Revenues are projected to grow approximately 10% annually, reaching USD 1.3 billion globally by 2025.
- Optimistic Scenario (Expanded Indications & Market Penetration): Clinical trial results lead to accelerated approval in additional tumor types. This increases market share to 15%, with a concomitant rise in pricing negotiations, pushing annual revenues toward USD 1.5-1.8 billion by 2025.
- Pessimistic Scenario (Price Erosion & Competition): Entry of biosimilars in 2024 and policy changes limit price increases. Anticipated price reductions of 20-30% in the next two years could lower revenues to USD 700-900 million.
Supply Chain & Cost Considerations
Manufacturing costs for monoclonal antibodies average USD 1,000-2,000 per dose, influenced by active pharmaceutical ingredient (API) complexity, biosafety measures, and scale of production. High production costs sustain premium pricing but face downward pressure from biosimilars and process innovations.
Competitive Landscape & Future Trends
- Biosimilar Entry: Patent expirations scheduled for 2024 open opportunities for biosimilar versions, decreasing average drug prices.
- Regulatory Developments: Fast-track approvals for combination regimens or biosimilars can further impact pricing and market share.
- Market Expansion: Investigations into earlier lines of therapy and novel indications, such as adjuvant settings, can expand total addressable markets.
Key Takeaways
- NDC 00093-0711 is a high-value oncology immunotherapy with growing sales driven by increased indications and adoption.
- Price stability is likely in the short term, but market pressures from biosimilars, reimbursement policies, and competitive approvals could lead to modest reductions.
- Revenue projections suggest a potential for USD 1.3-1.8 billion globally by 2025, with significant variability based on regulatory and market developments.
Frequently Asked Questions
-
What are the main factors influencing the price of NDC 00093-0711?
Pricing depends on clinical efficacy, manufacturing costs, reimbursement negotiations, competition from biosimilars, and strategic marketing.
-
How does biosimilar entry impact the drug's market?
Biosimilars typically lead to price reductions of 20-30%, reduce market share for the originator, and increase access through lower costs.
-
What are the key competitors, and how do they compete?
Key competitors include pembrolizumab, nivolumab, and atezolizumab, competing through efficacy data, approved indications, and pricing strategies.
-
What future developments could affect the market for NDC 00093-0711?
Expanded indications, combination therapies, and regulatory approvals in new tumor types can enlarge the market. Conversely, biosimilar challenges may suppress price growth.
-
How do pricing trends compare internationally?
US prices are generally higher; Europe and Asia implement stricter price controls, impacting revenue and pricing strategies globally.
References
- EvaluatePharma, "Oncology Market Overview," 2022.
- FDA, "Biologics License Application Approvals," 2017.
- IQVIA, "Global Oncology Market Data," 2022.
- US CMS Provider Pricing Data, 2023.
- Biosimilar Market Reports, "Impact on Oncology Monoclonal Antibodies," 2022.
